Sales & Marketing News | pharmaphorum

News

Grifols' executive chairman Thomas Glanzmann (l) and chief executive Nacho Abia (r)

Could Spain’s Grifols be heading for de-listing?

The family that owns Spanish drugmaker Grifols and private equity firm Brookfield are considering whether to take the company private in a deal that could be worth around €5.5 billion (almo

News

Four drugmakers found to have breached ABPI code

Novartis, Pfizer, Otsuka and Novo Nordisk have been called out by the UK’s Prescription Medicines Code of Practice Authority (PMCPA) for breaching the Association of the British Pharmaceuti

News

Private equity firms ‘eyeing $20bn for Sanofi consumer unit’

Private equity firms Bain Capital and Cinven are reported to be considering a bid for Sanofi’s consumer health business, according to Bloomberg.

News

Judge kicks out another Medicare price negotiation challenge

A Connecticut federal judge has sided with the US Department of Health and Human Services (HHS) in Boehringer Ingelheim's challenge to Medicare’s drug price negotiation programme, rejecting

News

EU first to approve Dupixent for COPD

Chronic obstructive pulmonary disease (COPD) has seen no new therapies brought to market for around 10 years – and now there have been two in the space of a couple of weeks.

News

Lilly gets FDA OK for Alzheimer’s drug, cites cost advantage

Eli Lilly finally has FDA approval for its amyloid-busting Alzheimer’s disease therapy donanemab and will launch it at a cost it claims could deliver savings compared to a rival therapy fro

Could Spain’s Grifols be heading for de-listing?

Four drugmakers found to have breached ABPI code

Private equity firms ‘eyeing $20bn for Sanofi consumer unit’

Judge kicks out another Medicare price negotiation challenge

EU first to approve Dupixent for COPD

Lilly gets FDA OK for Alzheimer’s drug, cites cost advantage

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks